Tyrosine kinase inhibitorFDA-approvedFirst-line
Cotellic
Generic name: cobimetinib
How it works
Blocks the MEK protein, a downstream target of the BRAF V600E mutation, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 9.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.